Phase 2 Clinical Trial for Non-Segmental Vitiligo (NSV) – Now Enrolling

1. Who Can Participate?

You may be eligible if you:

• Are between 18 and 65 years of age
• Have been diagnosed with non-segmental vitiligo (NSV) by a physician
• Have had vitiligo for at least 3 months
• Have received previous vitiligo treatment with insufficient response, or are unable to use standard therapies

2. What Does the Study Involve?

• Study duration: approximately 42 weeks
• Treatment period: the investigational drug will be administered once every 2 weeks for a total of 12 infusions
• Route of administration: intravenous (IV) infusion
• Study procedures may include:
  • Physical examinations
  • Blood and urine tests
  • Electrocardiogram (ECG)
  • Chest X-ray
  • Vitiligo photography and assessments

3. Potential Benefits and Risks

Possible Benefits

• Opportunity to receive an investigational treatment for vitiligo (benefit cannot be guaranteed)
• Regular health monitoring and vitiligo assessments throughout the study

Possible Risks

Possible side effects may include:

• Immune-related or allergic reactions (such as fever, rash, or nausea)
• Headache
• Muscle aches

All participants will be closely monitored by the study medical team throughout the trial.

Principal Investigator

Chau Yee Ng, MD
Department of Dermatology, Chang Gung Memorial Hospital, Linkou

Recruitment Now Open

For more information, please contact:

Study Coordinators: Min-Yi Chou, RN / Man-Ting Lin, RN

Phone: +886 922-216-828 / +886 928-577-665